Literature DB >> 16149092

The epigenome as a molecular marker and target.

David Gius1, C Matthew Bradbury, Lunching Sun, Rania T Awwad, Lei Huang, Dee Dee K Smart, Kheem S Bisht, Allen S Ho, Phuongmai Nguyen.   

Abstract

Tumor cell proliferation, de-differentiation, and progression depend on a complex combination of altered cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. The understanding of these complex mechanisms should lead to the identification of potential molecular markers, targets, and molecular profiles that should eventually expand and improve therapeutic intervention. It now appears clear that methylation plays a central role in transformation, both in vitro and in vivo. However, the exact targets and mechanism(s) are not yet fully understood. This is partly due to the significant number of genes altered by changes in intracellular methyltransferase activity and the chemical agents used to modulate gene expression. The complex nature of methylation's role in regulating gene expression suggests that in addition to investigating individual genes, researchers should develop more comprehensive methods to examine gene expression patterns and their predictive value as this will likely be necessary in the future. If methylation plays a role in transformation, then it seems logical that genes regulating intracellular methylation status may be used as molecular markers to profile tumors by any new methods currently being developed. Perhaps more noteworthy is that DNMT genes may be found to be novel molecular targets for new factor-specific anticancer agents. This idea will be addressed. Published 2005 by the American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16149092     DOI: 10.1002/cncr.21395

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Methylation determines fibroblast activation and fibrogenesis in the kidney.

Authors:  Wibke Bechtel; Scott McGoohan; Elisabeth M Zeisberg; Gerhard A Müller; Hubert Kalbacher; David J Salant; Claudia A Müller; Raghu Kalluri; Michael Zeisberg
Journal:  Nat Med       Date:  2010-04-25       Impact factor: 53.440

2.  Integrating Epigenomics into Pharmacogenomic Studies.

Authors:  Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal:  Pharmgenomics Pers Med       Date:  2008-11

Review 3.  Use of cell lines in the investigation of pharmacogenetic loci.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

4.  Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas.

Authors:  H Jin; X Wang; J Ying; A H Y Wong; H Li; K Y Lee; G Srivastava; A T C Chan; W Yeo; B B Y Ma; T C Putti; M L Lung; Z-Y Shen; L-Y Xu; C Langford; Q Tao
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

5.  Aberrant DNA Methylation of P16, MGMT, and hMLH1 Genes in Combination with MTHFR C677T Genetic Polymorphism in gastric cancer.

Authors:  Binbin Song; Jiang Ai; Xianghong Kong; Dexin Liu; Jun Li
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.